Dyadic International Receives $3 Million Grant From Gates Foundation for Monoclonal Antibody Development Targeting RSV and Malaria
Express News | Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for Rsv and Malaria Using C1 Platform Technology
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript Summary
Express News | HC Wainwright & Co. Reiterates Buy on Dyadic International, Maintains $6 Price Target
Dyadic International Reports Q3 2024 Growth and Strategic Advances
ceoram : @Jaguar8 sleeper and upcoming earning report. Had a short run until it hit a sell off from what I’m seeing. Would like your perspective.